A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Aromasin
Sponsor: Pfizer